A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to Compare Safety, Efficacy, and Pharmacodynamics of Single and Multiple Doses of ORMD-0801 in Adult Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Oramed Pharmaceuticals
- 11 Jul 2018 Status changed from recruiting to completed.
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 09 Nov 2016 New trial record